监管机构批准扩大晚期乳腺癌临床试验规模，格林威治生命科学公司股价上涨

路透中文07-20 20:36

BUZZ-监管机构批准扩大晚期乳腺癌临床试验规模，格林威治生命科学公司股价上涨

7月20日 - ** 生物科技公司格林威治生命科学（Greenwich LifeSciences，股票代码： GLSI.O）的股价在盘前交易中上涨6.6%，至17.39美元

** 该公司表示，美国和欧洲监管机构已批准其研究方案的变更，以扩大针对实验性乳腺癌免疫疗法glsi-100的晚期临床试验

** 该试验旨在验证glsi-100能否预防HER2阳性乳腺癌（一种常见的乳腺癌类型）在手术和治疗后复发

** 公司计划在美国和欧洲近200个试验点将入组规模扩大至多达2,000名患者，并计划将试验范围扩展至其他国家

** 该公司表示，方案调整将使更多患者符合入组条件，从而加快患者招募速度，并有助于更早获得研究结果

** 来自开放标签组的初步数据显示癌症复发率有所降低，但该公司表示结果仍处于早期阶段，可能会有变化

** 截至上一交易日收盘，该公司股价年内累计下跌约22%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652921587?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-07-20 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652921587","market":"hk","top_or_hot":-1,"title":"监管机构批准扩大晚期乳腺癌临床试验规模，格林威治生命科学公司股价上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-监管机构批准扩大晚期乳腺癌临床试验规模，格林威治生命科学公司股价上涨</title></head><body><p><span>7月20日</span><span> - </span>** 生物科技公司格林威治生命科学（Greenwich LifeSciences，股票代码： <span>GLSI.O</span>）的股价在盘前交易中上涨6.6%，至17.39美元</p><p>** 该公司表示，美国和欧洲监管机构已批准其研究方案的变更，以扩大针对实验性乳腺癌免疫疗法glsi-100的晚期临床试验</p><p>** 该试验旨在验证glsi-100能否预防HER2阳性乳腺癌（一种常见的乳腺癌类型）在手术和治疗后复发</p><p>** 公司计划在美国和欧洲近200个试验点将入组规模扩大至多达2,000名患者，并计划将试验范围扩展至其他国家</p><p>** 该公司表示，方案调整将使更多患者符合入组条件，从而加快患者招募速度，并有助于更早获得研究结果</p><p>** 来自开放标签组的初步数据显示癌症复发率有所降低，但该公司表示结果仍处于早期阶段，可能会有变化 </p><p>** 截至上一交易日收盘，该公司股价年内累计下跌约22%</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>监管机构批准扩大晚期乳腺癌临床试验规模，格林威治生命科学公司股价上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n监管机构批准扩大晚期乳腺癌临床试验规模，格林威治生命科学公司股价上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-07-20 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-监管机构批准扩大晚期乳腺癌临床试验规模，格林威治生命科学公司股价上涨</title></head><body><p><span>7月20日</span><span> - </span>** 生物科技公司格林威治生命科学（Greenwich LifeSciences，股票代码： <span>GLSI.O</span>）的股价在盘前交易中上涨6.6%，至17.39美元</p><p>** 该公司表示，美国和欧洲监管机构已批准其研究方案的变更，以扩大针对实验性乳腺癌免疫疗法glsi-100的晚期临床试验</p><p>** 该试验旨在验证glsi-100能否预防HER2阳性乳腺癌（一种常见的乳腺癌类型）在手术和治疗后复发</p><p>** 公司计划在美国和欧洲近200个试验点将入组规模扩大至多达2,000名患者，并计划将试验范围扩展至其他国家</p><p>** 该公司表示，方案调整将使更多患者符合入组条件，从而加快患者招募速度，并有助于更早获得研究结果</p><p>** 来自开放标签组的初步数据显示癌症复发率有所降低，但该公司表示结果仍处于早期阶段，可能会有变化 </p><p>** 截至上一交易日收盘，该公司股价年内累计下跌约22%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLSI","symbol_name":"Greenwich Lifesciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nL4T43M0VM:1","article_id":"2652921587","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652921587","pubTimestamp":1784550994,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-监管机构批准扩大晚期乳腺癌临床试验规模，格林威治生命科学公司股价上涨7月20日-** 生物科技公司格林威治生命科学（Greenwich LifeSciences，股票代码：GLSI.O）的股价在盘前交易中上涨6.6%，至17.39美元** 该公司表示，美国和欧洲监管机构已批准其研究方案的变更，以扩大针对实验性乳腺癌免疫疗法glsi-100的晚期临床试验** 该试验旨在验证glsi-100","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"GLSI":"Greenwich Lifesciences Inc","BK4139":"生物科技"},"translate_title":"Greenwich Life Sciences shares rise as regulators approve expansion of advanced breast cancer clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLSI":0.9},"content_text":"BUZZ-监管机构批准扩大晚期乳腺癌临床试验规模，格林威治生命科学公司股价上涨7月20日 - ** 生物科技公司格林威治生命科学（Greenwich LifeSciences，股票代码： GLSI.O）的股价在盘前交易中上涨6.6%，至17.39美元** 该公司表示，美国和欧洲监管机构已批准其研究方案的变更，以扩大针对实验性乳腺癌免疫疗法glsi-100的晚期临床试验** 该试验旨在验证glsi-100能否预防HER2阳性乳腺癌（一种常见的乳腺癌类型）在手术和治疗后复发** 公司计划在美国和欧洲近200个试验点将入组规模扩大至多达2,000名患者，并计划将试验范围扩展至其他国家** 该公司表示，方案调整将使更多患者符合入组条件，从而加快患者招募速度，并有助于更早获得研究结果** 来自开放标签组的初步数据显示癌症复发率有所降低，但该公司表示结果仍处于早期阶段，可能会有变化 ** 截至上一交易日收盘，该公司股价年内累计下跌约22%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652921587","isCrawlerRequest":true}